Large B-cell lymphoma: The LYSA pragmatic guidelines.

Area of Science:

• Hematology
• Oncology
• Clinical Medicine

Background:

• Large B-cell lymphomas (LBCL) management has evolved significantly in the past five years.
• New therapeutic options, including immunotherapies, cell therapies, and targeted molecules, have emerged.
• Improved understanding of LBCL biology and enhanced diagnostic tools have advanced patient care.

Purpose of the Study:

• To present pragmatic guidelines for the management of large B-cell lymphomas (LBCL).
• To integrate the latest evidence from clinical trials, expert consensus, and real-world practice.
• To provide clinicians with a framework for optimizing LBCL patient care.

Main Methods:

• Development of guidelines by the Lymphoma Study Association (LYSA).
• Inclusion of key aspects: diagnosis, staging, response evaluation, and treatment.
• Integration of evidence from clinical trials, expert consensus, and real-world data.

Main Results:

• Guidelines address diagnosis, staging, response evaluation, and treatment strategies for LBCL.
• The guidelines incorporate recent therapeutic advances and biological insights.
• Focus on balancing treatment efficacy and toxicity for optimal patient outcomes.

Conclusions:

• The LYSA guidelines offer a practical framework for managing LBCL.
• These guidelines aim to translate the best available evidence into clinical practice.
• Optimized care through evidence-based strategies is expected to enhance patient outcomes in LBCL.